Our precision oncology activities are focused on the development and implementation of methods and tools to identify actionable genomic alterations in cancer. Particular emphasis is on using an integrated approach in the evaluation of somatic (tumor) and the background germline (constitutional) genomic data to inform the role of germline alterations in cancer and their effect on clinical management and therapeutic decisions. To date, we have demonstrated the utility of tumor-derived somatic data in the assessment of the pathogenicity of germline variants in several cancer syndromes. INT²GRATE (INTegrated INTerpretation of GeRmline And Tumor gEnomes) is a multi-institutional consortium that includes several cancer programs aimed at identifying germline alterations with clinical utility. INT²GRATE algorithms incorporate tumor-derived somatic profiles in selected cancers with key clinical genetic information to aid interpretation of germline variants and assessment of their clinical utility in cancer. INT²GRATE facilitates the assembly of integrated evidence from tumor and germline data to promote data sharing. For more information, see the INT²GRATE | Oncology Consortium webpage and INT²GRATE Programs webpage.